Yoko Furukawa-Hibi

7PUBLICATIONS
31CO-AUTHORS
Haematological tumoursWastewater treatment processesPharmacogenomicsPredictive and prognostic markersNanoelectronics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 01, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

|Apr 02, 2026
Time-saving impact of two generation model chemotherapy compounding robots on pharmacists' daily workflow: A long-term evaluation.

Yuki Tonogai, Masahiro Kondo, Yasuhiro Horita

|Feb 26, 2026
Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Yoshihisa Mimura, Takaomi Sanda, Rei Unno

|Jan 06, 2025
Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information.

Kaori Ambe, Yuka Aoki, Miho Murashima

|May 21, 2024
The Effects of a Red-Light Controllable Nitric Oxide Donor, NORD-1, on Erectile Dysfunction in Rats with Streptozotocin Induced Diabetes Mellitus.

Yuji Hotta, Kyoya Oyama, Takuma Yoshida

|May 07, 2023
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.

Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto

Pageof 2

Frequent Collaborators

3 joint publications

Taku Naiki

2 joint publications

Kazunori Kimura

2 joint publications

Yosuke Sugiyama

2 joint publications

Yasuhiro Horita